A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
PHASE3
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic d...
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
PHASE2
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pha...
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
PHASE3
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes...
Status
Active Not Recruiting
Location
Gastro Health Research - St. Vincent'S East /ID# 275089
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
PHASE3
Crohn's disease (CD) is a long-lasting condition causing inflammation that ...
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
PHASE3
The objective of Study M15-991 is to evaluate the efficacy and safety of ri...